Melanoma: Clinical practice guidelines in oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 7, 2006, Pages 666-684

  Houghton, Alan N ^a   Coit, Daniel G ^a   Daud, Adil ^b   Dilawari, Raza A ^c   DiMaio, Dominick ^d   Gollob, Jared A ^e   Haas, Naomi B ^f   Halpern, Allan ^a   Johnson, Timothy M ^g   Kashani Sabet, Mohammed ^h   Kraybill, William G ⁱ   Lange, Julie R ^j   Martini, Mary ^k   Ross, Merrick I ^l   Samlowski, Wolfram E ^m   Sener, Stephen F ^k   Tanabe, Kenneth K ⁿ   Thompson, John A ^o   Trisal, Vijay ^p   Urist, Marshall M ^q   Walker, Michael J ^r   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ Dana Farber/Partners CancerCare   (United States)

^o SEATTLE CANCER CARE ALLIANCE   (United States)

^p City of Hope Cancer Center   (United States)

^q UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^r OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Adjuvant therapy; Biopsy; Chemotherapy; Interferon; Melanoma; Metastases; NCCN Clinical Practice Guidelines; Radiation therapy; Sentinel lymph node; Skin cancer; Surgical excision

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; OBLIMERSEN; TEMOZOLOMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HUMAN; LYMPH NODE DISSECTION; MELANOMA; ONCOLOGY; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR BIOPSY; ALGORITHM; ARTICLE; BIOPSY; LYMPHADENECTOMY; METASTASIS; METHODOLOGY; RECURRENT DISEASE; SKIN TUMOR;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LYMPH NODE EXCISION; MELANOMA; NEOPLASM METASTASIS; RECURRENCE; SKIN NEOPLASMS;

EID: 33747681022     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0057     Document Type: Review

References (61)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Desmond RA, Soong SJ. Epidemiology of malignant melanoma. Surg Clin North Am 2003;83:1-29.
3. Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.
4. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
5. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
6. Huang X, Soong S, McCarthy WH, et al. Classification of localized melanoma by the exponential survival trees method. Cancer 1997;79:1122-1128.
7. American Academy of Dermatology. Guidelines of care for primary cutaneous melanoma. Available at: http://www.aadassociation.org/professional/guidelines. Accessed June 9, 2005.
8. National Institutes of Health. After treatment of early melanoma, should patients and family members be followed? Why and how? NIH Consensus Statement 1992;10:1-26.
9. Wang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:399-405.
10. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252-258.
11. Buzaid AC, Sandler AR, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638-643.
12. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging patients with melanoma metastatic to regional nodes. Ann Surg Oncol 1997;4:396-402.
13. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis, Cancer 1993;72:3091-3098.
14. Veronesi U, Cascinelli N. Narrow excision (1-cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-441.
15. Batch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm) - results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262-267.
16. Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the square procedure. J Am Acad Dermatol 1997;37:758-764.
17. Zitelli JA, Brown C, Hanusa RH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997;37:236-245.
18. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage 1 malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
19. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage 1 primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-1162
20. [published erratum appears in N Engl J Med 1991;325:292].
21. Batch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-263.
22. Morton DL, Thompson JR, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenecromy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-463.
23. Kang JC, Wanek LA, Essner R, et al. Sentinel lymphadenectomy does nor increase rhe incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005;23:4764-4770.
24. Edwards MJ, Matrin KD, McMasters KM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Surg Oncol 1998;7:51-57.
25. Glass FL, Cottam JA, Reintgen HS. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol 1998;39:603-610.
26. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13:302-309.
27. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311; discussion 311-313.
28. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162-166.
29. Shen P, Conforti AM, Essner R, et al. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J 2000;6:93-97
30. Coit DG. Extent of groin dissection for melanoma. Surg Oncol Clin N Am 1992;1:271-280.
31. Yao KA, Hsuch EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003;238:743-747.
32. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (RCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-990.
33. Fraker DL, Coit DG. Isolated perfusion of extremity tumors. In: Lotze MT, Rubin JT, eds. Regional Therapy of Advanced Cancer. Philadelphia, Lippincott-Raven; 1997:333-350.
34. Lindner P, Doubrovsky A, Kam PC, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-136.
35. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002;9:762-770.
36. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarhazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166.
37. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995;2:445-449.
38. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2h adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST-1684. J Clin Oncol 1996;14:7-17.
39. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2h in high-risk melanoma: first analysis of intergroup trial E 1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
40. Kirkwood JM, Ibrahim JO, Sosman JA, et al. High-dose interferon alfa-2h significantly prolongs relapse-free and overall survival compared with the GM2- KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.
41. Lens MR, Dawes M. Interferon alpha therapy for malignant melanoma: a systematic review of randomized clinical trials. J Clin Oncol 2002;20:1818-1825.
42. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.
43. Hancock BW, Whearley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53-61.
44. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:1189-1196.
45. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.
46. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. Dermatology 1995;191:199-203.
47. Weiss M, Loprinzi CL, Greagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 1995;274:1703-1705.
48. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647-1654.
49. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990;212:173-177.
50. Kang S, Barnhill R, Mihm MC, et al. Multiple primary cutaneous melanoma. Cancer 1992;70:1911-1916.
51. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatr 1993;50:681-689.
52. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi-markers for increased risk for melanoma. Cancer 1989;63:386-389.
53. Gutman M, Cnaan A, Inbar M, et al. Are malignant melanoma patients at higher risk for a second cancer? Cancer 1991;68:660-665.
54. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.
55. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2751.
56. Kirkwood JM, Bedikian AY, Millward MJ, et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM) [abstract]. J Clin Oncol 2005;23: Abstract 7506.
57. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001-9007.
58. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-1125.
59. Weber RW, O'Day S, Rose M, et al. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005;23:8992-9000.
60. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
61. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357.